Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins
- 28 July 2008
- journal article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 27 (52), 6646-6656
- https://doi.org/10.1038/onc.2008.259
Abstract
Defects in the apoptotic signaling cascades contribute to the poor therapeutic response of malignant gliomas. As glioblastomas are characterized by high expression levels of anti-apoptotic Bcl-2 family proteins, we studied the effects of the novel Bcl-2 inhibitor, ABT-737, on malignant glioma cells. ABT-737 treatment released the pro-apoptotic Bax protein from its binding partner Bcl-2 and potently induced apoptotic cell death in glioblastoma cells in vitro and in vivo. The local administration of ABT-737 prolonged the survival in an intracranial glioma xenograft model. Downregulation of Mcl-1 and overexpression of Bcl-2 sensitized the cells to ABT-737-mediated apoptosis. Moreover, ABT-737 potentiated the cytotoxicity of the chemotherapeutic drugs vincristine and etoposide, and of the death ligand TRAIL. As glioma stem cells may play a crucial role for the tumor progression and the resistance to treatment in glioblastomas, we investigated the effects of ABT-737 on the subpopulation of glioma cells exhibiting stem cell characteristics. Inhibition of proliferation and induction of apoptosis by ABT-737 were less efficient in glioma stem cells than in non-stem cell-like glioma cells. As the resistance of glioma stem cells was associated with high Mcl-1 expression levels, ABT-737 treatment combined with downregulation of Mcl-1 could represent a promising novel approach in glioblastoma treatment.Keywords
This publication has 49 references indexed in Scilit:
- Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 MimeticsPLoS Medicine, 2007
- Mcl-1 Down-regulation Potentiates ABT-737 Lethality by Cooperatively Inducing Bak Activation and Bax TranslocationCancer Research, 2007
- Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737JCI Insight, 2007
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myelomaOncogene, 2006
- Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family membersCancer Cell, 2006
- Antiglioma activity of 2,2′:6′,2ʺ-terpyridineplatinum(II) complexes in a rat model—Effects on cellular redox metabolismFree Radical Biology & Medicine, 2006
- Subversion of the Bcl-2 Life/Death Switch in Cancer Development and TherapyCold Spring Harbor Symposia on Quantitative Biology, 2005
- Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosisCell Death & Differentiation, 2004
- Bcl-2 overexpression decreases BCNU sensitivity of a human glioblastoma line through enhancement of catalase activityJournal of Cellular Biochemistry, 2001